Celldex concludes Phase IIb enrolment for breast cancer drug
US-based Celldex Therapeutics has concluded patient enrolment in Phase IIb METRIC clinical trial of glembatumumab vedotin to treat metastatic triple negative breast cancer characterised by over-expression of gpNMB. (Source: Drug Development Technology)
Source: Drug Development Technology - August 24, 2017 Category: Pharmaceuticals Source Type: news
Deals this week: Atreca, Calithera Biosciences, Spring Bank Pharmaceuticals
US-based biotechnology company Atreca has secured $35m in a series B financing round led by Wellington Management Company. (Source: Drug Development Technology)
Source: Drug Development Technology - August 24, 2017 Category: Pharmaceuticals Source Type: news
Outsourcing in Clinical Trials Pacific Northwest-Outsourcing in Clinical Trials Pacific Northwest
(Source: Drug Development Technology)
Source: Drug Development Technology - August 24, 2017 Category: Pharmaceuticals Source Type: news
Outsourcing in Clinical Trials Southern California 2017-Outsourcing in Clinical Trials Southern California
(Source: Drug Development Technology)
Source: Drug Development Technology - August 24, 2017 Category: Pharmaceuticals Source Type: news
Outsourcing in Clinical Trials Midwest 2017-Outsourcing in Clinical Trials Midwest 2017
(Source: Drug Development Technology)
Source: Drug Development Technology - August 24, 2017 Category: Pharmaceuticals Source Type: news
Nerlynx (neratinib) for the Treatment of Breast Cancer
Nerlynx ™ (neratinib) is a tyrosine kinase inhibitor indicated for the treatment of adult patients with early-stage HER2-overexpressed or amplified breast cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - August 23, 2017 Category: Pharmaceuticals Source Type: news
Zealand partner Boehringer begins Phase I trials for two obesity and / or diabetes drugs
Zealand Pharma has announced the launch of two Phase I clinical trials by its partner Boehringer Ingelheim to investigate a glucagon / GLP-1 agonist and an amylin analogue for the treatment of obesity and / or type 2 diabetes. (Source: Drug Development Technology)
Source: Drug Development Technology - August 23, 2017 Category: Pharmaceuticals Source Type: news
Cancer Research UK begins new trial for advanced cancer drug
Cancer Research UK has initiated a clinical trial of LY3143921 hydrate at four clinical sites in the country to treat patients with advanced solid tumours. (Source: Drug Development Technology)
Source: Drug Development Technology - August 23, 2017 Category: Pharmaceuticals Source Type: news
Bonti launches Phase II trial of EB-001 for musculoskeletal pain
US-based biotechnology firm Bonti has launched a Phase II clinical trial (LANTERN-1) of EB-001 to treat patients with musculoskeletal pain. (Source: Drug Development Technology)
Source: Drug Development Technology - August 23, 2017 Category: Pharmaceuticals Source Type: news
Pfizer and AFT initiate Phase III trial of HER2+ breast cancer drug
Pfizer and the Alliance Foundation Trials have partnered with six international cancer research groups to initiate a Phase III clinical trial (PATINA) of palbociclib (IBRANCE) in patients with hormone receptor-positive (HR+), human epidermal growth f … (Source: Drug Development Technology)
Source: Drug Development Technology - August 22, 2017 Category: Pharmaceuticals Source Type: news
Astellas starts dosing gilteritinib patients in Phase III trial to treat AML
Astellas Pharma has started dosing patients with gilteritinib in a Phase III MORPHO clinical trial for the treatment of acute myeloid leukaemia (AML). (Source: Drug Development Technology)
Source: Drug Development Technology - August 22, 2017 Category: Pharmaceuticals Source Type: news
Ovid begins randomisation in Phase Ib/IIa trial of epilepsy drug
Ovid Therapeutics has begun patient randomisation in a Phase Ib/IIa clinical trial of TAK-935 (OV935) to treat adults with rare epilepsies. (Source: Drug Development Technology)
Source: Drug Development Technology - August 22, 2017 Category: Pharmaceuticals Source Type: news
Bod Australia concludes Phase I trial design for cannabis extract
Natural medicines developer Bod Australia has concluded the design for a Phase I clinical trial of its pharmaceutical grade cannabis extract in combination with a new delivery system. (Source: Drug Development Technology)
Source: Drug Development Technology - August 21, 2017 Category: Pharmaceuticals Source Type: news
Novartis and MMV initiate Phase IIb trial of KAF156 for malaria in Africa
Novartis and Medicines for Malaria Venture (MMV) have initiated a Phase IIb clinical trial of KAF156 to treat multidrug-resistant malaria in Africa. (Source: Drug Development Technology)
Source: Drug Development Technology - August 21, 2017 Category: Pharmaceuticals Source Type: news
MatriSys commences dosing in Phase IIa trial for atopic dermatitis
MatriSys Bioscience has started dosing patients with a lotion containing Staphylococcus hominis (S. hominis) in a Phase IIa clinical trial to treat adults with moderate-to-severe atopic dermatitis (AD). (Source: Drug Development Technology)
Source: Drug Development Technology - August 21, 2017 Category: Pharmaceuticals Source Type: news
